Abstract
The long-term use of dopamine replacement therapy leads to dyskinesias in some Parkinson’s disease (PD) patients, which may be specific to the D1 subtype of dopamine (DA) receptor. The purpose of this study was to test the effectiveness of a D2-specific DA agonist, Pramipexole, in PD patients. In a double-blind design, 6 patients took increasing doses of Pramipexole over the course of 24 weeks, and were tested in a total of 15 sessions on four measures of movement efficacy: tapping speed, simple response time, choice response time, and sequencing. Compared with 3 placebo control patients, those on active medication showed faster tapping speeds and simple response times. Choice response time and sequencing were not affected by medication status. The D2 subtype of DA receptor may be especially important in movement speed, and may contribute less to more cognitive aspects of movement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
